Overview

Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab

Status:
Active, not recruiting

Trial end date:
2023-06-01

Target enrollment:

Participant gender:

Summary

Phase III randomized trial of the anti-PD-L1 antibody avelumab as adjuvant or post-neoadjuvant treatment for high-risk triple negative breast cancer patients. The overall protocol-defined patient population will include the following two strata of patients: - Stratum A - Patients who have completed treatment with curative intent including surgery of the primary tumor followed by adjuvant chemotherapy . - Stratum B - Patients who have completed treatment with curative intent including neoadjuvant chemotherapy followed by surgery of the primary tumor and (if indicated) further adjuvant chemotherapy.

Phase:

Phase 3

Details

Lead Sponsor:

Istituto Oncologico Veneto IRCCS

Collaborators:

Dipartimento di scienze chirurgiche, Oncologiche e Gastroenterologiche
University of Padova

Treatments:

Antibodies
Avelumab